These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 2570698

  • 1. Clinical significance of the sparteine/debrisoquine oxidation polymorphism.
    Brøsen K, Gram LF.
    Eur J Clin Pharmacol; 1989; 36(6):537-47. PubMed ID: 2570698
    [Abstract] [Full Text] [Related]

  • 2. [Role of pharmacogenetics in psychopharmacotherapy].
    Gram LF.
    Encephale; 1991; 17 Spec No 1():123-5. PubMed ID: 1864259
    [Abstract] [Full Text] [Related]

  • 3. Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism.
    Fonne-Pfister R, Meyer UA.
    Biochem Pharmacol; 1988 Oct 15; 37(20):3829-35. PubMed ID: 2903741
    [Abstract] [Full Text] [Related]

  • 4. The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism.
    Ebner T, Eichelbaum M.
    Br J Clin Pharmacol; 1993 Apr 15; 35(4):426-30. PubMed ID: 8485023
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [The significance of cytochrome P450 gene superfamily for the clinical pharmacokinetics of drugs].
    Brøsen K.
    Ugeskr Laeger; 1991 Feb 04; 153(6):417-22. PubMed ID: 2000644
    [Abstract] [Full Text] [Related]

  • 8. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.
    Otton SV, Brinn RU, Gram LF.
    Drug Metab Dispos; 1988 Feb 04; 16(1):15-7. PubMed ID: 2894945
    [Abstract] [Full Text] [Related]

  • 9. Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians.
    Lennard MS, Iyun AO, Jackson PR, Tucker GT, Woods HF.
    Pharmacogenetics; 1992 Apr 04; 2(2):89-92. PubMed ID: 1302046
    [Abstract] [Full Text] [Related]

  • 10. Polymorphic oxidation of debrisoquine and sparteine.
    Eichelbaum M.
    Prog Clin Biol Res; 1986 Apr 04; 214():157-67. PubMed ID: 3523506
    [No Abstract] [Full Text] [Related]

  • 11. Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics.
    Brosen K.
    Clin Pharmacokinet; 1990 Mar 04; 18(3):220-39. PubMed ID: 2182263
    [Abstract] [Full Text] [Related]

  • 12. The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects.
    Eichelbaum M, Gross AS.
    Pharmacol Ther; 1990 Mar 04; 46(3):377-94. PubMed ID: 2188269
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Deficient metabolism of debrisoquine and sparteine.
    Inaba T, Otton SV, Kalow W.
    Clin Pharmacol Ther; 1980 Apr 04; 27(4):547-9. PubMed ID: 7357813
    [Abstract] [Full Text] [Related]

  • 19. Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol.
    Gut J, Catin T, Dayer P, Kronbach T, Zanger U, Meyer UA.
    J Biol Chem; 1986 Sep 05; 261(25):11734-43. PubMed ID: 3745165
    [Abstract] [Full Text] [Related]

  • 20. Debrisoquine polymorphism: novel CYP2D6 gene Bam HI restriction fragment length polymorphism in the Ngawbé Guaymí Indian of Panama.
    Petersen DD, Kong AN, Jorge LF, Nebert DW, Arias TD.
    Pharmacogenetics; 1991 Dec 05; 1(3):136-42. PubMed ID: 1688244
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.